Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma

International Journal of Cancer

Volumn 134, Issue 6, 2014, Pages 1300-1310

  Tsen, Andrew R ^a   Long, Patrick M ^a   Driscoll, Heather E ^b   Davies, Matthew T ^a   Teasdale, Benjamin A ^a   Penar, Paul L ^a   Pendlebury, William W ^a   Spees, Jeffrey L ^a   Lawler, Sean E ^c   Viapiano, Mariano S ^c   Jaworski, Diane M ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NORWICH UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

aspartoacylase; epigenetics; glioblastoma; glioma; glyceryl triacetate; metabolism; oligodendroglioma; triacetin

Indexed keywords

ACETIC ACID; FOOD ADDITIVE; TEMOZOLOMIDE; TRIACETIN; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CANAVAN DISEASE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EVENING DOSAGE; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LONG TERM SURVIVAL; MESENCHYME CELL; MONOTHERAPY; MORNING DOSAGE; MOUSE; NEURAL STEM CELL; NONHUMAN; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PHENOTYPE; PRIORITY JOURNAL; SUPPLEMENTATION;

EID: 84891835684     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28465     Document Type: Article

References (50)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
2. Parkinson JF, Afaghi V, Payne CA, et al. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre. J Clin Neurosci 2011; 18: 329-33.
3. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
4. Rigotti DJ, Kirov II, Djavadi B, et al. Longitudinal whole-brain N-acetylaspartate concentration in healthy adults. AJNR Am J Neuroradiol 2011; 32: 1011-5.
5. Kaul R, Casanova J, Johnson AB, et al. Purification, characterization, and localization of aspartoacylase from bovine brain. J Neurochem 1991; 56: 129-35.
6. Goldberg RP, Brunengraber H,. Contributions of cytosolic and mitochondrial acetyl-CoA syntheses to the activation of lipogenic acetate in rat liver. Adv Exp Med Biol 1980; 132: 413-8.
7. Fujino T, Kondo J, Ishikawa M, et al. Acetyl-coA synthetase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate. J Biol Chem 2001; 276: 11420-6.
8. Moffett JR, Ross B, Arun P, et al. N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81: 89-131.
9. Long PM, Moffett JR, Namboodiri AMA, et al. N-acetylaspartate (NAA) and N-acetylaspartylglutamate (NAAG) promote growth and inhibit differentiation of glioma stem-like cells. J Biol Chem 2013; 288: 26188-200.
10. Trotter J, Bitter-Suermann D, Schachner M,. Differentiation-regulated loss of the polysialylated embryonic form and expression of the different polypeptides of the neural cell adhesion molecule by cultured oligodendrocytes and myelin. J Neurosci Res 1989; 22: 369-83.
11. Soliman ML, Rosenberger TA,. Acetate supplementation increases brain histone acetylation and inhibits histone deacetylase activity and expression. Mol Cell Biochem 2011; 352: 173-80.
12. Soliman ML, Smith MD, Houdek HM, et al. Acetate supplementation modulates brain histone acetylation and decreases interleukin-1β expression in a rat model of neuroinflammation. J Neuroinflammation 2012; 9: 51.
13. Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009; 27: 2052-8.
14. Lee EQ, Puduvalli VK, Reid JM, et al. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res 2012; 18: 6032-9.
15. Lluri G, Langlois GD, Soloway PD, et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) regulates myogenesis and b1 integrin expression in vitro. Exp Cell Res 2008; 314: 11-24.
16. Long PM, Stradecki HM, Minturn JE, et al. Differential aminoacylase expression in neuroblastoma. Int J Cancer 2011; 129: 1322-30.
17. Jaworski DM, Pérez-Martínez L,. Tissue inhibitor of metalloproteinase-2 (TIMP-2) expression is regulated by multiple neural differentiation signals. J Neurochem 2006; 98: 234-47.
18. Shimada IS, LeComte MD, Granger J, et al. Self-renewal and differentiation of reactive astrocyte-derived neural stem/progenitor cells isolated from cortical peri-infarct tissues after stroke. J Neurosci 2012; 32: 7926-40.
19. Godlewski J, Nowicki MO, Bronisz A, et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res 2008; 68: 9125-30.
20. An Z, Gluck CB, Choy ML, et al. Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture. Cancer Lett 2010; 292: 215-27.
21. Orzan F, Pellegatta S, Poliani PL, et al. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol 2011; 37: 381-94.
22. Pérez-Martínez L, Jaworski DM,. Tissue inhibitor of metalloproteinase-2 promotes neuronal differentiation by acting as an anti-mitogenic signal. J Neurosci 2005; 25: 4917-29.
23. Jaworski DM, Kelly GM, Piepmeier JM, et al. BEHAB (Brain Enriched Hyaluronan Binding) is expressed in surgical samples of glioma and in intracranial grafts of invasive glioma cell lines. Cancer Res 1996; 56: 2293-8.
24. Trissel LA, Zhang Y, Koontz SE,. Temozolomide stability in extemporaneously compounded oral suspensions. Int J Pharm Compound 2006; 10: 396-9.
25. King BJ, Plante MK, Kida M, et al. Comparison of intraprostatic ethanol diffusion using a microporous hollow fiber catheter versus a standard needle. J Urol 2012; 187: 1898-902.
26. Moffett JR, Arun P, Ariyannur PS, et al. Extensive aspartoacylase expression in the rat central nervous system. Glia 2011; 59: 1414-34.
27. Lamoral-Theys D, Le Mercier M, Le Calvé B, et al. Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. Neoplasia 2010; 12: 69-79.
28. Jijiwa M, Demir H, Gupta S, et al. CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS One 2011; 6: e24217.
29. Long PM, Tsen AR, Moffett JR, et al. Dietary acetate supplementation as a means of inducing glioma stem cell growth arrest. Am Assoc Cancer Res 2012; 3481: 12.
30. Menendez JA, Lupu R,. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7: 763-77.
31. Seligson DB, Horvath S, McBrian MA, et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009; 174: 1619-28.
32. Wellen KE, Hatzivassiliou G, Sachdeva UM, et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009; 324: 1076-80.
33. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391-400.
34. Chinnaiyan P, Kensicki E, Bloom G, et al. The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res 2012; 72: 5878-88.
35. Mathew R, Arun P, Madhavarao CN, et al. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain. J Pharmacol Exp Ther 2005; 315: 297-303.
36. Donohoe DR, Collins LB, Wali A, et al. The warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell 2012; 48: 612-26.
37. Wolańczyk M, Hułas-Bigoszewska K, Witusik-Perkowska M, et al. Imperfect oligodendrocytic and neuronal differentiation of glioblastoma cells. Folia Neuropathol 2010; 48: 27-34.
38. Rieske P, Golanska E, Zakrzewska M, et al. Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors. BMC Cancer 2009; 9: 54.
39. Ricci-Vitiani L, Pallini R, Larocca LM, et al. Mesenchymal differentiation of glioblastoma stem cells. Cell Death Differ 2008; 15: 1491-8.
40. Abdouh M, Facchino S, Chatoo W, et al. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 2009; 29: 8884-96.
41. Suvà ML, Riggi N, Janiszewska M, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009; 69: 9211-8.
42. Natsume A, Ito M, Katsushima K, et al. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer Res 2013; 73: 4559-70.
43. Bailey JW, Haymond MW, Miles JM,. Triacetin: a potential parenteral nutrient. J Parenter Enteral Nutr 1991; 15: 32-6.
44. Stafford P, Abdelwahab MG, Kim DY, et al. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond) 2010; 7: 74.
45. Fiume MZ, Panel. CIRE,. Final report on the safety assessment of triacetin. Int J Toxicol 2003; 22 (Suppl 2): 1-10.
46. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-6.
47. Segel R, Anikster Y, Zevin S, et al. A safety trial of high dose glyceryl triacetate for Canavan disease. Mol Genet Metab 2011; 103: 203-6.
48. Friday BB, Anderson SK, Buckner J, et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol 2012; 14: 215-21.
49. Kitange GJ, Mladek AC, Carlson BL, et al. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res 2012; 18: 4070-9.
50. Raynal NJ, Si J, Taby RF, et al. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res 2012; 72: 1170-81.